David Liu

Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC).

C. Drake, H. Scher, C. Logothetis, 2014 .

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

L. Jeng, M. Kudo, P. Philip, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY

Masatoshi Kudo, Yoon-Koo Kang, Won Young Tak, 2012 .

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

M. Kudo, J. Bruix, M. Sherman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

N. Agarwal, C. Drake, H. Scher, 2014, The Lancet. Oncology.

EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer.

P. Aguiar, R. D. De Mello, H. Tadokoro, 2016, Recent Patents on Anti-Cancer Drug Discovery.